Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer

NCT00407251 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT00407251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00407251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
Not reported
Enrollment
73 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory prostate cancer